Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation

KRAS(G12D), the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRAS(G12D) inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuting, Zhang, Hai, Li, Jindong, Niu, Miao-Miao, Zhou, Yang, Qu, Yuanqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815544/
https://www.ncbi.nlm.nih.gov/pubmed/36618907
http://dx.doi.org/10.3389/fphar.2022.1094887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815544/
https://www.ncbi.nlm.nih.gov/pubmed/36618907
http://dx.doi.org/10.3389/fphar.2022.1094887

Ejemplares similares